Ascletis completes enrollment of phase iii trial of asc40 (denifanstat) once-daily oral tablet for treatment of acne

-phase iii trial enrolled a total of 480 patients with moderate to severe acne -topline results expected in the second quarter 2025 hangzhou, china , nov. 12, 2024 /prnewswire/ -- ascletis pharma inc. (hkex: 1672, "ascletis") today announces completion of enrollment of 480 patients for phase iii clinical trial of asc40 (denifanstat) o nce-daily oral tablet for treatment of moderate to severe acne. the first patient was enrolled on january 24, 2024.
ASC Ratings Summary
ASC Quant Ranking